John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer

Patrick Soon-Shiong made several fortunes based on his understanding of cancer and drug development, most recently in today's multibillion-dollar IPO for NantKwest. And now he plans to put the IPO money to use in pursuit of a new strategy in immuno-oncology R&D--the single hottest field in the industry.

Immunomedics blasted after UCB lupus PhIIIs fail

UCB says that its two Phase III trials for their lupus drug epratuzumab failed. The developer said that neither of the two doses used in the identical, late-stage trials proved statistically superior to a placebo.

Cutting-edge research centers back Deerfield's $550M biotech venture fund

Some of the world's top research institutions are backing a new, $550 million biotech venture fund from Deerfield Management.

UPDATED: Billionaire Soon-Shiong scores a record-setting $2.6B IPO for NantKwest

Last year Conkwest was just another small, largely unknown biotech with big plans in immuno-oncology. But after biotech billionaire Patrick Soon-Shiong bought in and took the CEO title, renaming the company NantKwest, it's now leaping onto the scene with a record-setting IPO that establishes a market cap baseline at a whopping $2.6 billion.

UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology

A few months after conceding that its own in-house attempt to develop new cancer drugs had flopped, French pharma giant Sanofi will now let its close development partner Regeneron lead the way on a blockbuster collaboration on immuno-oncology--which includes an early-stage checkpoint inhibitor.

Boehringer dumps its Alzheimer's BACE pact with Vitae

Shares of Vitae Pharmaceuticals dropped 5% this morning after the biotech reported that Boehringer Ingelheim had decided to dump its collaboration on a new BACE program for Alzheimer's.

Nymox soars after claims of a post-PhIII BPH turnaround

Late last year shares of Nymox were put into the shredder after the biotech said that both of its late-stage studies for their lead drug for enlarged prostates had flopped. But the biotech rebounded today after the company claimed that an extension of those studies had produced positive results.

Allergan joins the hunt for a 'transformational' biotech deal

In a conversation with Forbes' Matthew Herper, Allergan CEO Brent Saunders happily spotlighted his bolt-on buyouts with Kythera, Naurex, Furiex and Rhythm. Compare that to recent remarks from Eli Lilly's John Lechleiter, who has always insisted on backing the pipeline he has while adding an occasional pact, or Severin Schwan at Roche. Both see this current market as overpriced.

Eli Lilly soldiers on in big PhIII evacetrapib study

Eli Lilly says that it will push ahead to the end on its Phase III study of evacetrapib, a CETP inhibitor that hopes to succeed where other giants have failed.

UPDATED: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout

The big news in biopharma this weekend is the unconfirmed report that Allergan is looking to sell its generics business to Teva. But Allergan execs didn't let the headlines distract them from another goal of CEO Brent Saunders': building the pipeline.